Filing Flows › Recursion Pharmaceuticals (RXRX) › Grant revenue revenue
Recursion Pharmaceuticals (RXRX) Grant revenue revenue by quarter
Recursion Pharmaceuticals' Grant revenue revenue was $497K in Q3 2026 (third quarter 2026), +35% from Q2 2026. Over the last 6 quarters it ranged from $120K (Q2 2025) to $497K (Q3 2026).
| Quarter | Grant revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $497K | +35% | +159% |
| Q2 2026 | $367K | +115% | +206% |
| Q1 2026 | $171K | -9% | — |
| Q4 2025 | $187K | -3% | — |
| Q3 2025 | $192K | +60% | — |
| Q2 2025 | $120K | — | — |
Q3 2026 at a glance
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Recursion Pharmaceuticals' Grant revenue revenue?
Recursion Pharmaceuticals' Grant revenue revenue was $497K in Q3 2026 (third quarter 2026), +35% from Q2 2026.
How has Recursion Pharmaceuticals' Grant revenue revenue changed?
Over the last 6 quarters it ranged from $120K (Q2 2025) to $497K (Q3 2026).
Q3 2026 results → · How Recursion Pharmaceuticals makes money →